Experience With H.P. Acthar Gel Treatment of Patients With Nephrotic Syndrome/Proteinuria Due to Various Etiologies and Its Effect on Podocyte Function

Status unconfirmed

Conditions studied: Decrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte Function

In brief

Patients with proteinuria to start treatment with Acthar and watch a variety of clinical parameters with a goal of decreasing proteinuria between 50-100% over a period of nine months with every 3 months increasing the dose of medication until a decrease of either 50- 100 % of protein excretion is achieved. In addition addition podocyte function will be assessed monthly by measuring suPar levels, tnf alpha, podocyte/creatinine levels as well as podocyte function studies.

Key facts

Study ID

NCT03644771

Run by

Greater Boston Medical Associates

People needed

40

Starts

2017-01-25

Expected to finish

2021-12-31

Last updated by the study team

2020-02-05

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients with proteinuria as above. patients with controlled conditions below are candidates.

You may not qualify if…

• uncontrolled hypertension,diabetes mellitus, congestive heart failure, coronary artery disease, peripheral vascular disease.

Where it is running

• Greater Boston Medical Associates 211 West St. — Milford, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.